ACCC is committed to ensuring that cancer patients have access to the entire continuum of quality cancer care, including access to the most appropriate cancer therapies.
On September 11, 2023, ACCC submitted comment letters to the Centers for Medicare and Medicaid Services (CMS) on the proposed physician fee schedule (PFS) and hospital outpatient prospective payment system (OPPS) regulations. Among other topics, ACCC
supported the proposal for Medicare reimbursement for principal illness navigation (PIN) services to assist those with serious illnesses such as cancer.Read the First Letter
Read the Second Letter
On Tuesday, August 15, ACCC hosted a webinar for all members to review the proposed OPPS and PFS rules with Teri Bedard, RT (R)(T), CPC, ACCC's coding and billing specialist. Download the full presentation.
National shortages of anti-cancer drugs, including cisplatin, carboplatin, and methotrexate, reached an all-time high during the first quarter of 2023. The Association of Community Cancer Centers (ACCC) recognizes the significant stress and concern caused by the scarcity of life-saving drugs for cancer patients nation-wide.
Dive in to learn about the advocacy efforts ACCC has championed to help patients and providers navigate cancer care under the current conditions.
Issues related to the oncology drug shortage prompted seven oncology care experts to gather for a roundtable discussion, Critical Conversation: National Drug Shortages and Empowering Oncology Pharmacists. ACCC has shared a recording and a transcript of their conversation.
Download the Q&A Transcript
In partnership with Hematology/Oncology Pharmacy Association (HOPA) and Association of VA Hematology/Oncology (AVAHO).
Last year, the Center for Medicare & Medicaid Innovation (the Innovation Center) announced the Enhancing Oncology Model (EOM)—the Oncology Care Model's successor. Now, the Innovation Center has released two resources to help EOM stakeholders understand the model's health equity strategy and new enhanced services requirement.
The application period for the EOM closed on October 10, 2022, and the Centers for Medicare & Medicaid Services is in the process of reviewing submitted applications in advance of the model launch on July 1, 2023.
For more information on the EOM, visit its dedicated its dedicated website, email its support team, or call 1.888.734.6433, option 3.
On August 29, 2022, the Centers for Medicare & Medicaid Services (CMS) published a final rule (CMS-5527-F2) that finalized delaying the Radiation Oncology Model start date until a date is determined through future rulemaking.
For more information, visit the Radiation Oncology Model website.
On June 27, 2022, the Biden Administration, through the Department of Health and Human Services and Centers for Medicare & Medicaid Services (CMS), announced a new model to improve cancer care for Medicare patients: the Enhancing Oncology Model (EOM). This model is the successor to the Oncology Care Model (OCM).
The EOM—designed by the Center for Medicare and Medicaid Innovation—will tackle the health inequities and meet patients' throughout the cancer care continuum, with an emphasis on person-centered care and better patient outcomes. The model will run from July 2023 through June 2028, and its participants will include oncology practices that treat people with Medicare undergoing chemotherapy for breast cancer, chronic leukemia, lung cancer, lymphoma, multiple myeloma, prostate cancer, and small intestine/colorectal cancer.
For additional information regarding the EOM, visit the CMS website. Then read ACCC's statement.